title: [Clinical and pathological study on effects of Qianggan Capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B].
abstract: OBJECTIVE
  To study the therapeutic effects of Qianggan Capsule (QC) combined Lamivudine on hepatic fibrosis in patients with chronic hepatitis B.
  
  
  METHODS
  Eighty-five patients were randomly divided into two groups, group A (40 cases) were treated with QC and Lamivudine and group B (45 cases) were treated with QC alone both for 6 months. Hepatic fibrosis related indexes and pathologic examination of liver biopsy were performed within 3 months before treatment and in 1 month after treatment.
  
  
  RESULTS
  Serum levels of hyaluronic acid, collagen N and laminin decreased markedly after treatment in both groups (P < 0.05). Hepatic histopathological examination showed that the total effective rate of impovement in activity of inflammation-necrosis and fibrosis was 80.0% and 70.0% in group A, 57.8% and 75.6% in group B, respectively, the combined treatment showed a better effect in improving the activity of inflammation-necrosis than QC alone (P < 0.05), but with no significant difference to the latter in improving fibrosis.
  
  
  CONCLUSIONS
  QC combined Lamivudine could markedly reduce the activity of hepatic inflammation-necrosis, QC alone could also improve hepatic fibrosis.
authors.affiliation: The People's Hospital of Lianjiang City, Guangdong. zjwanghua@avl.com
authors.forename: Hua
authors.initials: H
authors.lastname: Wang
authors.forename: Yan-long
authors.initials: YL
authors.lastname: Zhao
authors.forename: Ke-cheng
authors.initials: KC
authors.lastname: Xu
mesh_terms: D000328:Adult; D002214:Capsules; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000821:virology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D018894:Reverse Transcriptase Inhibitors; C527657:qianggan; D019259:Lamivudine